Dernières nouvelles pour Cresco Labs (OTC:CRLBF) Stock

Cresco Labs

Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture and sell retail and medical cannabis products through Sunnyside, Cresco Labs' national dispensary brand and others. The company operates in one segment, the cultivation, manufacturing, distribution and sale of cannabis.

Cresco Labs Inc

Loop Capital analyst Garik Shmois maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Hold and lowers the price target from $65 to $62.

News

Price Target

Analyst Ratings

Loop Capital Maintains Hold on Masco, Lowers Price Target to $62

<a href="https://www.youtube.com/live/3vzdyqVIJT0?si=0x2eEkt5troZbqVg">https://www.youtube.com/live/3vzdyqVIJT0?si=0x2eEkt5troZbqVg</a>

General

Fed's Kashkari Says I'm Worried That Amid Uncertainties Businesses Will Do Layoffs; Says Not Seeing Uptick In Layoffs Yet; Says Some Businesses Say They Are Scenario Planning For Potential Layoffs If Uncertainty Lasts

Loop Capital analyst Alton Stump maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and lowers the price target from $65 to $63.

Loop Capital Maintains Buy on Chipotle Mexican Grill, Lowers Price Target to $63

Macro Economic Events

Economics

Fed's Kashkari Says A Resolution Of Trade Frictions Would Relieve Uncertainty, Would Be Optmistic; Says Crypto Is Useless In An Advanced Economy; It's Been 15 Years And Use-case Hasn't Been Demonstrated; Says Up To Congress To Regulate Crypto

Loop Capital analyst Anthony Chukumba maintains PROG Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRG#NYSE">PRG</a>) with a Buy and lowers the price target from $45 to $40.

Loop Capital Maintains Buy on PROG Holdings, Lowers Price Target to $40

Barclays analyst Julian Mitchell maintains Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Equal-Weight and raises the price target from $180 to $185.

Barclays Maintains Equal-Weight on Dover, Raises Price Target to $185

Barclays analyst Michael Leithead maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Equal-Weight and lowers the price target from $38 to $32.

Barclays Maintains Equal-Weight on Dow, Lowers Price Target to $32

AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) has outperformed the market over the past 15 years by 4.8% on an annualized basis producing an average annual return of 15.51%. Currently, AMETEK has a market capitalization of $38.59 billion. 
Buying $100 In AME: If an investor had bought $100 of AME stock 15 years ago, it would be worth $853.85 today based on a price of $167.24 for AME at the time of writing.
<h3>AMETEK's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745531128_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $560 to $513.

Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $513

Barclays analyst Matthew Bouley maintains Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) with a Overweight and lowers the price target from $70 to $69.

TMHC

Barclays Maintains Overweight on Taylor Morrison Home, Lowers Price Target to $69

Celestica Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) reported first-quarter financial results Thursday after the bell. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/g44995314/celestica-announces-first-quarter-2025-financial-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $2.65 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $2.61 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $1.20, versus estimates of $1.15</li>
</ul>
&#8220;Celestica delivered a strong&nbsp;first quarter&nbsp;in 2025, achieving revenue of&nbsp;$2.65 billion&nbsp;and non-GAAP adjusted EPS of&nbsp;$1.20, both surpassing the high end of our&nbsp;guidance&nbsp;ranges. This strong performance was further highlighted by our highest ever adjusted operating margin of&nbsp;7.1%,&#8221; said Rob Mionis, president and CEO of Celestica.
&#8220;With these results, and a strengthening demand&nbsp;outlook&nbsp;from our CCS customers, we are raising our full-year 2025&nbsp;outlook.&#8221;
See Also: <a href="https://www.benzinga.com/25/04/44995955/alphabet-q1-earnings-highlights-google-search-youtube-cloud-show-robust-momentum">Alphabet Q1 Earnings Highlights: Google Search, YouTube, Cloud Show &#8216;Robust Momentum&#8217;</a>
Outlook: Celestica guided for second-quarter revenue of $2.58 billion to $2.73 billion versus estimates of $2.77 billion. The company expects second-quarter adjusted earnings to be in the range of $1.17 to $1.27 per share versus <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates of $1.24 per share. 
The company also raised its full-year 2025 outlook. Celestica raised its full-year revenue guidance from $10.7 billion to $10.85 billion, and raised its earnings outlook from $4.75 per share to $5 per share. The guidance is still below analyst estimates of $12.54 billion in revenue and earnings of $5.76 per share. 
The company noted that its guidance assumes no material changes to tariffs compared to what&#8217;s currently in effect, and no material changes from current macroeconomic trends and uncertainties. 
Celestica executives will further discuss the quarter on a call with investors and analysts Friday morning at 8 a.m. ET.
CLS Price Action: <a href="http://benzinga.com/quote/cls">Celstica shares</a> were down 3.25% after-hours, trading at $89.15 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: •<a href="https://www.benzinga.com/news/earnings/25/04/44997163/boston-beer-reports-strong-eps-beat-shipment-growth-in-q1"> Boston Beer Reports Strong EPS Beat, Shipment Growth In Q1</a>
Photo: Shutterstock.

Earnings

Guidance

After-Hours Center

Movers

Celestica Beats Q1 Estimates, Raises FY Outlook On 'Strengthening Demand,' Shares Slide

Barclays analyst Brandon Oglenski maintains Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Equal-Weight and lowers the price target from $32 to $26.

Barclays Maintains Equal-Weight on Southwest Airlines, Lowers Price Target to $26

Barclays analyst Raimo Lenschow maintains ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) with a Overweight and raises the price target from $967 to $969.

Barclays Maintains Overweight on ServiceNow, Raises Price Target to $969

<a href="https://www.bloomberg.com/news/articles/2025-04-24/hertz-eyes-500-million-debt-raise-ahead-of-litigation-payment">https://www.bloomberg.com/news/articles/2025-04-24/hertz-eyes-500-million-debt-raise-ahead-of-litigation-payment</a>

'Hertz Eyes $500 Million Debt Raise Ahead of Litigation Payment'- Bloomberg

Barclays analyst Manav Patnaik maintains Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) with a Equal-Weight and lowers the price target from $50 to $45.

Barclays Maintains Equal-Weight on Robert Half, Lowers Price Target to $45

Barclays analyst Jared Shaw maintains Popular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPOP#NASDAQ">BPOP</a>) with a Overweight and raises the price target from $115 to $125.

BPOP

Barclays Maintains Overweight on Popular, Raises Price Target to $125

MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) soared on Thursday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44974556/marinemax-reports-fiscal-2025-second-quarter-results" rel="noreferrer noopener">reported second-quarter results.</a>
The company reported adjusted earnings per share of 23 cents, beating the street view of 19 cents. Quarterly sales of $631.51 million (+8.3% year over year), outpacing the analyst consensus estimate of $578.77 million.
&#8220;Despite facing a weak retail market and an uncertain macroeconomic climate, we delivered a strong second-quarter performance,&#8221; said Brett McGill, Chief Executive Officer.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/04/44979310/durable-goods-orders-jump-9-2-in-march-but-one-category-tells-the-real-story" rel="noreferrer noopener">Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story</a>
An increase in boat sales primarily drove the top-line growth. On a comparable same-store basis, revenue increased by 11%, reflecting additional contributions from products and services, including finance and insurance, the Superyachts Division, manufacturing and marinas.
Gross profit decreased 0.5% year over year to $189.5 million, while gross profit margin of 30.0% decreased 270 basis points.
This was primarily due to lower boat margins and the challenging retail environment. Adjusted EBITDA&nbsp;for the quarter increased to $30.9 million from $29.6 million for the comparable period last year.
&#8220;We ended the quarter with more than $200 million in cash and cash equivalents, and continue to reduce our long-term debt. Additionally, we have significant financing capacity through largely unused lines of credit,&#8221; McGill added.
Outlook: MarineMax expects fiscal year 2025 adjusted net income&nbsp;in the range of $1.40 to $2.40 per diluted share (estimate: $2.28), compared with a prior range of $1.80 to $2.80 per diluted share.
&#8220;The level of actual new sales seems to have slowed since the start of April. This suggests growing concern among consumers about the actual effects to the economy from the tariffs,&#8221; the CEO added.
Price Action: HZO shares closed higher by 17.30% to $22.67&nbsp;on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44996394/chipotle-battles-slumping-sales-but-honey-chicken-boosts-hope-say-analysts" target="_blank" rel="noreferrer noopener">Chipotle Battles Slumping Sales, Analyst Pin Hope On Honey Chicken</a></li>
</ul>
Photo by Macklin Holloway via Shutterstock

Equities

Markets

Why Did MarineMax Stock Soar On Thursday

Barclays analyst Raimo Lenschow maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Equal-Weight and raises the price target from $84 to $96.

PEGA

Barclays Maintains Equal-Weight on Pegasystems, Raises Price Target to $96

Barclays analyst Brandon Oglenski maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Equal-Weight and lowers the price target from $185 to $170.

ODFL

Barclays Maintains Equal-Weight on Old Dominion Freight Line, Lowers Price Target to $170

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and lowers the price target from $75 to $71.

Comments

Cresco Labs

Actualités

Dernières nouvelles pour Cresco Labs (OTC:CRLBF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL